<html>
<head>
  <title>SARS-CoV-2 Spike protein (S) gene L18F;T20N;P26S;D138Y;R190S;K417T;E484K;N501Y;D614G;H655Y;T1027I literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="S.html">Spike protein (S)</a> gene <span class="constellation">S:p.L18F;T20N;P26S;D138Y;R190S;K417T;E484K;N501Y;D614G;H655Y;T1027I</span> literature reference collection</h1>
<div class="effect_section"><h2 id="ACE2_receptor_binding_affinity">ACE2 receptor binding affinity</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma)  showed a 4.24x increase in binding (KD) relative to D614G.<br/> (<a href="https://doi.org/10.1101/2021.08.04.455140" class="lit_link">Gong et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="convalescent_plasma_binding">Convalescent plasma binding</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> This variant combination (representing P.1 aka Gamma)  showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.<br/> (<a href="https://doi.org/10.1101/2021.08.04.455140" class="lit_link">Gong et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="convalescent_plasma_escape">Convalescent plasma escape</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Mean 4.1x reduction of NT50 value P.1 (Gamma) relative to wild type in 8 sera from older convalescent patients (52-92yo) collected 1-3m post symptom onset.<br/> (<a href="https://doi.org/10.1101/2021.09.06.459005" class="lit_link">Uriu et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="reinfection">Reinfection</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Three healthcare workers (29-50yo) had confirmed P.1 [Gamma] re-infection in the Amazonas region of Brazil 3-9 months after initial  infection from viruses with distinct lineage from P.1, but mild symptoms upon re-infection and evidence for infectiousness during re-infection.<br/> (<a href="https://doi.org/10.21203/rs.3.rs-318392/v1" class="lit_link">Naveca et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence).<br/>Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue). (<a href="https://doi.org/10.1590/S1678-9946202163036" class="lit_link">Malta Romano et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="trafficking">Trafficking</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> ~6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations.<br/> (<a href="https://doi.org/10.1101/2021.08.05.455290" class="lit_link">Esclera et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="vaccine_efficacy">Vaccine efficacy</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 349 test-positive were Gamma.<br/>Two dose vaccine efficacy against Gamma was 95.5 (90.9-97.8%), one dose VE was 74.2 (43.8-88.1%). (<a href="https://doi.org/10.1101/2021.09.29.21264199" class="lit_link">Bruxvoort et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="vaccine_neutralization_efficacy">Vaccine neutralization efficacy</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Mean 3.0x reduction of NT50 value P.1 (Gamma) relative to wild type in 8 sera from adult BNT162b2 vaccinees (28-47yo) collected ~1m post booster.<br/> (<a href="https://doi.org/10.1101/2021.09.06.459005" class="lit_link">Uriu et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="vaccinee_plasma_binding">Vaccinee plasma binding</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> This variant combination (representing P.1 aka Gamma)  showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. <br/> 1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.<br/> (<a href="https://doi.org/10.1101/2021.08.04.455140" class="lit_link">Gong et al. (2021)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
